Autor: "Picard, O." - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms.
Autorzy:: Ungar B; Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Malickova K; IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic.
Hanžel J; Department of Gastroenterology, University Medical Centre Ljubljana, Ljuljana, Slovenia.
Abu Arisha M; Rambam Health Care Campus, Bruce and Ruth Rappaport Faculty of Medicine, Haifa, Israel.
Paul S; Immunology Department, GIMAP CIC INSERM 1408, University of Lyon, Saint Etienne, France.
Rocha C; Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.; Instituto de Saúde Ambiental, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
Ben Shatach Z; Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abitbol CM; Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Haj Natour O; Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Selinger L; Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yavzori M; Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Fudim E; Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Picard O; Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shoval I; Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan, Ramat Gan, Israel.
Eliakim R; Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Kopylov U; Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Magro F; Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.
Roblin X; Department of Hepatogastroenterology, University Hospital of Saint Etienne, Saint Etienne, France.
Chowers Y; Rambam Health Care Campus, Bruce and Ruth Rappaport Faculty of Medicine, Haifa, Israel.
Drobne D; Department of Gastroenterology, University Medical Centre Ljubljana, Ljuljana, Slovenia.; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
Lukas M; IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic.
Ben Horin S; Gastroenterology Institute, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Oct 07; Vol. 15 (10), pp. 1707-1719.
Typ publikacji:: Journal Article; Multicenter Study; Observational Study
MeSH Terms:: Antibodies, Monoclonal, Humanized/*administration & dosage
Gastrointestinal Agents/*administration & dosage
Inflammatory Bowel Diseases/*drug therapy
Adult ; Biomarkers/analysis ; C-Reactive Protein/analysis ; Cell Adhesion Molecules/analysis ; Dose-Response Relationship, Drug ; Endoscopy, Gastrointestinal ; Female ; Humans ; Macrophages/drug effects ; Male ; Middle Aged ; Mucoproteins/analysis ; Serum Albumin/analysis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies.
Autorzy:: Ben-Horin S; Department of Gastroenterology, Sheba Medical Center Tel Hashomer & Sackler School of Medicine, Tel-Aviv University, Israel.; Department of Gastroenterology, First Affiliated Hospital, Sun YatSen University, Guangzhou, China.
Van Assche G; Division of Gastroenterology and Hepatology, University Hospitals Leuven, Belgium.
Chowers Y; Rambam Health Care Campus & Bruce Rappaport School of Medicine, Technion Institute of Technology, Haifa, Israel.
Fudim E; Department of Gastroenterology, Sheba Medical Center Tel Hashomer & Sackler School of Medicine, Tel-Aviv University, Israel.
Ungar B; Department of Gastroenterology, Sheba Medical Center Tel Hashomer & Sackler School of Medicine, Tel-Aviv University, Israel.
Picard O; Department of Gastroenterology, Sheba Medical Center Tel Hashomer & Sackler School of Medicine, Tel-Aviv University, Israel.
Yavzori M; Department of Gastroenterology, Sheba Medical Center Tel Hashomer & Sackler School of Medicine, Tel-Aviv University, Israel.
Kopylov U; Department of Gastroenterology, Sheba Medical Center Tel Hashomer & Sackler School of Medicine, Tel-Aviv University, Israel.
Mao R; Department of Gastroenterology, First Affiliated Hospital, Sun YatSen University, Guangzhou, China.
Chen MH; Department of Gastroenterology, First Affiliated Hospital, Sun YatSen University, Guangzhou, China.
Peled Y; The Olga and Lev Leviev Heart Center, Sheba Medical Center Tel Hashomer & Sackler School of Medicine, Tel-Aviv University, Israel.
Gueta I; Institute of Clinical Pharmacology, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Israel.
Eliakim R; Department of Gastroenterology, Sheba Medical Center Tel Hashomer & Sackler School of Medicine, Tel-Aviv University, Israel.
Loebstein R; Department of Gastroenterology, Sheba Medical Center Tel Hashomer & Sackler School of Medicine, Tel-Aviv University, Israel.
Markovits N; The Institute of Clinical Pharmacology, Sheba Medical Center Tel Hashomer & Sackler School of Medicine, Tel-Aviv University, Israel.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2018 Nov 28; Vol. 12 (12), pp. 1410-1417.
Typ publikacji:: Journal Article
MeSH Terms:: Inflammatory Bowel Diseases*/drug therapy
Inflammatory Bowel Diseases*/immunology
Inflammatory Bowel Diseases*/metabolism
Azathioprine/*pharmacokinetics
Bacterial Toxins/*immunology
Enterotoxins/*immunology
Guanine Nucleotides/*pharmacokinetics
Immune Reconstitution/*immunology
Mercaptopurine/*pharmacokinetics
Muromonab-CD3/*pharmacology
Superantigens/*immunology
Thionucleotides/*pharmacokinetics
Adult ; Cell Proliferation/drug effects ; Female ; Humans ; Immunosuppressive Agents/pharmacokinetics ; Male ; Metabolic Clearance Rate ; T-Lymphocytes/immunology ; Withholding Treatment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
Autorzy:: Ben-Horin S; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.; First Affiliated Hospital of Sun-Yatsen University, Guangzhou, China.
Ungar B; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Kopylov U; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Lahat A; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Yavzori M; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Fudim E; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Picard O; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Peled Y; Cardiology Department, Sheba Medical Center & Tel-Aviv University, Israel.
Eliakim R; Department of Gastroenterology, Sackler School of Medicine, Sheba Medical Center Tel Hashomer, Tel-Aviv University, Tel Aviv, Israel.
Del Tedesco E; Department of Gastroenterology, University Hospital of Saint Etienne, Saint Etienne, France.
Paul S; Department of Gastroenterology, University Hospital of Saint Etienne, Saint Etienne, France.
Roblin X; Department of Gastroenterology, University Hospital of Saint Etienne, Saint Etienne, France.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2018 Apr; Vol. 47 (8), pp. 1117-1125. Date of Electronic Publication: 2018 Feb 15.
Typ publikacji:: Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Adalimumab/*administration & dosage
Antibodies, Monoclonal, Humanized/*administration & dosage
Gastrointestinal Agents/*administration & dosage
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*administration & dosage
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Adalimumab/adverse effects ; Adalimumab/pharmacokinetics ; Adult ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Case-Control Studies ; Female ; Gastrointestinal Agents/adverse effects ; Gastrointestinal Agents/pharmacokinetics ; Humans ; Inflammatory Bowel Diseases/metabolism ; Infliximab/adverse effects ; Infliximab/pharmacokinetics ; Male ; Middle Aged

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Vedolizumab Levels in Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.
Autorzy:: Lahat A; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel, affiliated with Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shitrit AB; Digestive Diseases Institute, Shaare Zedek Medical Center, affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.
Naftali T; Gastroenterology institute, Meir Medical Center, Kfar Saba, affiliated with Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Milgrom Y; Digestive Diseases Institute, Shaare Zedek Medical Center, affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.
Elyakim R; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel, affiliated with Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Goldin E; Digestive Diseases Institute, Shaare Zedek Medical Center, affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.
Levhar N; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel, affiliated with Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Selinger L; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel, affiliated with Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Zuker T; Digestive Diseases Institute, Shaare Zedek Medical Center, affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.
Fudim E; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel, affiliated with Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Picard O; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel, affiliated with Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yavzori M; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel, affiliated with Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ben-Horin S; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel, affiliated with Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2018 Jan 05; Vol. 12 (1), pp. 120-123.
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: Antibodies, Monoclonal, Humanized/*analysis
Gastrointestinal Agents/*analysis
Inflammatory Bowel Diseases/*drug therapy
Milk, Human/*chemistry
Adult ; Antibodies, Monoclonal, Humanized/blood ; Antibodies, Monoclonal, Humanized/therapeutic use ; Breast Feeding ; Case-Control Studies ; Female ; Gastrointestinal Agents/blood ; Humans ; Prospective Studies ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
Autorzy:: Bar-Yoseph H; Department of Gastroenterology, Rambam Health Care Campus, Haifa, Israel.; Bruce Rappaport School of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
Levhar N; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Selinger L; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Manor U; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Yavzori M; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Picard O; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Fudim E; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Kopylov U; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Eliakim R; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Ben-Horin S; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Chowers Y; Department of Gastroenterology, Rambam Health Care Campus, Haifa, Israel.; Bruce Rappaport School of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
Ungar B; Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Ramat Gan, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2018 Jan; Vol. 47 (2), pp. 212-218. Date of Electronic Publication: 2017 Nov 09.
Typ publikacji:: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibodies/*blood
Biomarkers, Pharmacological/*blood
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*immunology
Infliximab/*therapeutic use
Adult ; Antibodies/analysis ; Biomarkers, Pharmacological/analysis ; Case-Control Studies ; Colitis, Ulcerative/blood ; Colitis, Ulcerative/diagnosis ; Colitis, Ulcerative/drug therapy ; Crohn Disease/blood ; Crohn Disease/diagnosis ; Crohn Disease/drug therapy ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Inflammatory Bowel Diseases/blood ; Inflammatory Bowel Diseases/diagnosis ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.
Autorzy:: Lim KJ; R&D Division, Celltrion Inc., Incheon, Korea.
Lee SJ; R&D Division, Celltrion Inc., Incheon, Korea.
Kim S; R&D Division, Celltrion Inc., Incheon, Korea.
Lee SY; R&D Division, Celltrion Inc., Incheon, Korea.
Lee MS; R&D Division, Celltrion Inc., Incheon, Korea.
Park YA; R&D Division, Celltrion Inc., Incheon, Korea.
Choi EJ; R&D Division, Celltrion Inc., Incheon, Korea.
Lee EB; R&D Division, Celltrion Inc., Incheon, Korea.
Jun HK; R&D Division, Celltrion Inc., Incheon, Korea.
Cho JM; R&D Division, Celltrion Inc., Incheon, Korea.
Lee S; R&D Division, Celltrion Inc., Incheon, Korea.
Kwon KS; R&D Division, Celltrion Inc., Incheon, Korea.
Lim BP; R&D Division, Celltrion Inc., Incheon, Korea.
Jeon MS; Translational Research Center and Inha Research Institute for Medical Sciences, Inha University School of Medicine, Incheon, Korea.
Shin EC; Laboratory of Immunology and Infectious Disease, Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea.
Choi YS; Department of Gastroenterology, Daehang Hospital, Seoul, Korea.
Fudim E; Department of Gastroenterology, Sheba Medical Center & Sackler School of Medicine, Tel-Aviv University, Ramat-Gan, Israel.
Picard O; Department of Gastroenterology, Sheba Medical Center & Sackler School of Medicine, Tel-Aviv University, Ramat-Gan, Israel.
Yavzori M; Department of Gastroenterology, Sheba Medical Center & Sackler School of Medicine, Tel-Aviv University, Ramat-Gan, Israel.
Ben-Horin S; Department of Gastroenterology, Sheba Medical Center & Sackler School of Medicine, Tel-Aviv University, Ramat-Gan, Israel.
Chang SJ; R&D Division, Celltrion Inc., Incheon, Korea.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2017 May 01; Vol. 11 (5), pp. 593-602.
Typ publikacji:: Journal Article
MeSH Terms:: Antibodies, Monoclonal/*pharmacology
Biosimilar Pharmaceuticals/*pharmacology
Gastrointestinal Agents/*pharmacology
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*pharmacology
Intestines/*drug effects
Antibodies, Monoclonal/therapeutic use ; Biosimilar Pharmaceuticals/therapeutic use ; Caco-2 Cells/drug effects ; Cytokines/metabolism ; Gastrointestinal Agents/therapeutic use ; Humans ; In Vitro Techniques ; Infliximab/therapeutic use ; Intestines/cytology ; Intestines/immunology ; Macrophages/drug effects ; Tumor Necrosis Factor-alpha/metabolism ; Wound Healing/drug effects

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.
Autorzy:: Ben-Horin S; Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel. />Mazor Y
Yanai H
Ron Y
Kopylov U
Yavzori M
Picard O
Fudim E
Maor Y
Lahat A
Coscas D
Eliakim R
Dotan I
Chowers Y; Pokaż więcej
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2012 Mar; Vol. 35 (6), pp. 714-22. Date of Electronic Publication: 2012 Jan 30.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Anti-Inflammatory Agents/*immunology
Antibodies, Monoclonal/*immunology
Antibodies, Monoclonal, Humanized/*immunology
Autoantibodies/*blood
Inflammatory Bowel Diseases/*drug therapy
Tumor Necrosis Factor-alpha/*immunology
Adalimumab ; Adult ; Aged ; Cohort Studies ; Female ; Humans ; Inflammatory Bowel Diseases/immunology ; Infliximab ; Male ; Middle Aged ; Prospective Studies ; Time Factors ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Picard, O."" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji